Skip to Content

Patients concerns about treatment with biosimilars

Biosimilars are not going to be the same as the originator biologic drug and that scares a lot of patients and doctors. They want to see basically the biosimilars treated as new drugs. In this MEDtalk Steve Feldman, professor of dermatology, share his experience with biosimilars.

Få adgang til artiklen

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top